A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

MiniMed Group, Inc. Common Stock MMED

Mixed broader-coverage candidate · MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company

On FrontierLab's discovery record since 2026-08-07 (8 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-16), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	16.4%
Gross margin	53.8%
Gross profits / assets	0.37
Rule of 40	16.9
Net margin	0.5%
Cash runway (months)	23.7
PEG	—
Price / sales	1.9

Quality checklist

~ Revenue growth — 16.4% (pass ≥ 20%)
✓ Gross profits / assets — 0.37 (pass ≥ 0.33)
~ Gross margin — 53.8% (pass ≥ 60%)
~ Cash generation

Fundamentals — snapshot as of 2026-09-16

Stage	Established
Share issuance (YoY)	—
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-1.10
Burn multiple	0
Gross-margin trend (pts)	—
Cash / assets	0.04
Net debt / EBITDA	-1.7
Statements as of	Q1 FY2026 · filed 2026-09-08

Momentum context — a snapshot from 2026-09-16, not current

Price at surface	$22.01 (as of 2026-09-16)
52-week range	$10.65 – $24.43
% off 52-wk high	-9.9%
RSI (14)	59
Relative volume	1×

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-16 (end-of-day). How grades are computed →